Publications by authors named "Axel Dignass"

Claim this Profile
D
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST Study.
Axel Dignass, Fernando Magro, Ferdinando D'Amico, Giorgos Bamias, Flavio Andrea Caprioli

United European Gastroenterol J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
Jurij Hanžel, Virginia Solitano, Sudheer Kumar Vuyyuru, Remo Panaccione, Bruce E Sands, Axel Dignass

Gastroenterology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Patients with Ulcerative Proctitis: A Global Survey.
Bénédicte Caron, Léa Sequier, Axel Dignass, Subrata Ghosh, Ailsa Hart

Dig Dis Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-survey.
Paula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, Mafalda Santiago, Walter Reinisch, Axel Dignass

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.
Adam S Faye, David T Rubin, Corey A Siegel, Millie D Long, Nabeel Khan, Axel Dignass

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.
Bruce E Sands, David T Rubin, Edward V Loftus, Douglas C Wolf, Remo Panaccione, Axel Dignass

Am J Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis.
Elisabeth Schnoy, Axel Dignass, Matthew Gaskins, Torsten Kucharzik

Z Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
Mariangela Allocca, Vipul Jairath, Bruce E Sands, David T Rubin, Bénédicte Caron, Axel Dignass

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment targets in IBD: is it time for new strategies?
Fabrizio Fanizzi, Ferdinando D'Amico, Laurent Peyrin-Biroulet, Silvio Danese, Axel Dignass

Best Pract Res Clin Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice.
Bénédicte Caron, Vipul Jairath, Bruce E Sands, David T Rubin, Mariangela Allocca, Axel Dignass

Clin Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Axel Dignass

Inflamm Bowel Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey.
Gionata Fiorino, Alissa Walsh, Michel Adamina, Manuel Barreiro-de Acosta, Mariam P Ali, Axel Dignass

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
Gionata Fiorino, Catarina Fidalgo, Michel Adamina, Manuel Barreiro-de Acosta, Mariam P Ali, Axel Dignass

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.
Sophie Vieujean, Bruce E Sands, Remo Panaccione, David T Rubin, Vipul Jairath, Axel Dignass

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inadequate Therapy Response on Advanced Therapy in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims Data.
Axel Dignass, Irina Blumenstein, Carolina Schwedhelm, Katrin Strassen, Leonie Kunk

United European Gastroenterol J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.
Virginia Solitano, Charles N Bernstein, Iris Dotan, Axel Dignass, Rhondell Domilici

Nat Rev Gastroenterol Hepatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis.
Tim Disher, Dominik Naessens, Myrlene Sanon, Ashley Bonner, Jenna Ellis, Axel Dignass

Adv Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data.
Axel Dignass, Niels Teich, Stephan Kaiser, Juliane Sünwoldt, Christina Dünweber

BMC Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Bruce E Sands, Laurent Peyrin-Biroulet, Stefan Schreiber, Silvio Danese, Alessandro Armuzzi, Axel Dignass

J Clin Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of histologic healing in IBD: Evidence from randomized controlled trials (RCT) and real world (RW) data.
Maria Manuela Estevinho, Joana Roseira, Pedro Vilela Teixeira, Axel Dignass, Fernando Magro

Dig Liver Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and Management of Upper Gastrointestinal Involvement in Adult Patients With Crohn's Disease: A Systematic Review.
Nathaniel A Cohen, Neta Sror, Maliha Naseer, Dominik Bettenworth, Cathy Lu, Axel Dignass

Clin Gastroenterol Hepatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease.
Ferdinando D'Amico, Sarah Bencardino, Fernando Magro, Axel Dignass, Ana Gutiérrez Casbas

Biologics· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis.
Suha Abushamma, Tesfaye Yadete, Neil Nero, Katherine Falloon, Claire E Parker, Axel Dignass

J Crohns Colitis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
David T Rubin, Jessica R Allegretti, Julián Panés, Nicole Shipitofsky, Shadi S Yarandi, Axel Dignass

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Application of advanced treatment in chronic inflammatory bowel diseases].
Benjamin Misselwitz, Sebastian Zeißig, Stefan Schreiber, Axel Dignass

Inn Med (Heidelb)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis